The recent success of obesity treatments, particularly Ozempic (semaglutide) and Mounjaro (tirzepatide), has driven significant interest in glucagon-like peptide-1 receptor (GLP1R) targeting drugs. These therapies have witnessed a 595% increase in licensing deal value between 2019 and 2024 year-to-date (YTD), exceeding $6.2 billion in 2024 YTD alone.